News - Ghost Supply

0 items / $0.00

0 items / $0.00

Home » Archive by Category "News" (Page 10)

25 May

ATS: Phase 2 Data Demonstrate the Superiority of Efdoralprin Alfa Over a Standard-of-Care Augmentation Therapy in Achieving Higher fAAT levels in AATD

May 25, 2026
By admin
0 comments

Paris, May 18, 2026. Data from the global ElevAATe phase 2 study (clinical study identifier: NCT05856331) demonstrated superiority of i...

Continue reading

25 May

Lilly’s Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial

May 25, 2026
By admin
0 comments

INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforgl...

Continue reading

25 May

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

May 25, 2026
By admin
0 comments

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics I...

Continue reading

25 May

Foundayo (orforglipron) was Associated with Reduced Body Weight of Up To 13% in Adults 65 and Older with Obesity or Overweight, in New Analysis of ATTAIN-1/2

May 25, 2026
By admin
0 comments

INDIANAPOLIS, May 22, 2026 – Eli Lilly and Company (NYSE: LLY) announced a new analysis from the Phase 3 ATTAIN-1 and ATTAIN-2 trials s...

Continue reading